UCB’s BIMZELX[®]▼ (bimekizumab) Gains Favorable CHMP Opinion for treatment Moderate to Severe Hidradenitis Suppurativa in Adults

UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion,…

Read MoreUCB’s BIMZELX[®]▼ (bimekizumab) Gains Favorable CHMP Opinion for treatment Moderate to Severe Hidradenitis Suppurativa in Adults

Pfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Pfizer Inc. (NYSE: PFE) has disclosed promising findings from a Phase 3 clinical trial investigating the efficacy of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in conjunction with lenalidomide and rituximab…

Read MorePfizer Reports Encouraging Overall Survival Results in Phase 3 Study of ADCETRIS® Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma